Treace Medical Reports Q2 2026 Revenue of $45.4M, Narrows Loss, and Raises Full-Year Revenue Guidance
TMCI has more than doubled off its 52-week low of $1.17.
Summary
Treace Medical Concepts reported Q2 2026 revenue of $45.4 million, a 4% decline year-over-year, but narrowed its net loss and raised the lower end of full-year revenue guidance, reflecting improving case volumes and new product traction.
Key Events · Earnings and Guidance · TMCI
-
Q2 Revenue Declines 4% to $45.4M
Second quarter 2026 revenue was $45.4 million, down from $47.4 million in Q2 2025, but showed sequential improvement in year-over-year growth rate.
-
Net Loss Narrows to $(15.9)M
Net loss improved to $(15.9) million, or $(0.24) per share, from $(17.4) million, or $(0.28) per share, a year ago, helped by an 8% reduction in operating expenses.
-
Full-Year Revenue Guidance Raised
Management raised the lower end of 2026 revenue guidance to $204 million (from $202 million), now expecting $204–$212 million, representing a decline of 4% to 0% vs. 2025.
-
Adjusted EBITDA Loss Guidance Tightened
Full-year adjusted EBITDA loss is now expected to be $3.0–$5.0 million, improved from prior guidance of a $4.0–$6.0 million loss, reflecting better cost control.
Analysis · TMCI · Industrial Applications And Services
Treace Medical Concepts delivered a mixed Q2 2026: revenue declined 4% year-over-year to $45.4 million, but the company narrowed its net loss to $(15.9) million from $(17.4) million a year ago, driven by an 8% reduction in operating expenses. Adjusted EBITDA improved slightly to $(3.5) million. More importantly, management raised the lower end of its full-year revenue guidance to $204 million (from $202 million) and tightened its adjusted EBITDA loss forecast to $3.0–$5.0 million, signaling confidence in accelerating case volumes and new product adoption in the second half. With $45.6 million in cash and marketable securities plus access to a $115 million credit facility, liquidity remains adequate to fund operations while the company continues to invest in its expanded bunion portfolio. The sequential improvement in surgeon adoption of new systems (40% vs. 35% in Q1) and the launch of SuperBite and HyperPlate XM provide tangible growth catalysts, though the top-line decline and ongoing losses keep the outlook cautious.
At the time of this filing, TMCI was trading at $4.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $284.1M. The 52-week trading range was $1.17 to $7.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.